Altimmune stock: 48-week pemvidutide MASH data, FDA Breakthrough Therapy boost, but rising competition and cash needs. Click ...
Altimmune's pemvidutide shows promise in treating MASH with obesity, potentially positioning it as a first-in-class drug targeting both liver health and weight loss. Despite past volatility, ALT stock ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results